| Autor: |
PROIETTI, ADRIAN E., ANGÓS, MARCIAL A., DAIN, ALEJANDRO, ECHENIQUE, MARIELA I., KABAKIAN, MARÍA L., PAZ, MARIA P., RAGGIO, MARCELA, RUBIN, GRACIELA B., SALEME, ANTONIO, SANTUCCI, MARIA P., CASTRO, MATIAS, DAGHERO, ANDREA, GROSEMBACHER, LUIS A. |
| Zdroj: |
Diabetes; 2021 Supplement 1, Vol. 70, pN.PAG-N.PAG, 1p |
| Abstrakt: |
Background and Aims: Despite recent technological advances, optimal glycemic control remains a challenge in people with type 1 diabetes (T1D). Hybrid closed loop (HCL) systems with automated algorithm-derived adjustment of basal insulin delivery, aims to improve glycemic control without adding additional therapy burden or educational investments. Aim: To evaluate the effectiveness of HCL system in Latin American subjects with T1D and who received a completely virtual training. Methods: Prospective observational data analysis that included consecutive patients with T1D that initiated treatment with MiniMed™ 670G system in Argentina. Baseline and follow up visits at days 28, 90 and 180 were carried out and data was downloaded from Carelink™ Personal at each visit. Patient training and follow-up were performed completely virtual through video conference. Results: A total of 104 patients were included, age: 32.8 ± 17.2 (range 8-77). Subjects were previously on MDI+SMBG (26%), MDI+isCGM (12.5%), CSII+SMBG (9.6%), CSII+isCGM (2.9%), and SAP-TS (49%). Baseline GMI was 7.3 ± 0.8%. Time in range (TIR) 70-180 mg/dl significantly increased regardless of prior therapy from 62.1±14.8 % at baseline to 74.6±8.6 %, 74.2±9.8 % and 74.3±9.6 % at days 28, 90 and 180 respectively (p<0,05). Mean glucose levels decreased from 166,1mg/dL at baseline to 152.9 mg/dL (p<0,05) at day 180. GMI was also reduced from 7.3% to 6.9% (p<0,05). Sensor wear time and Auto Mode use were 89.1% and 88.6% respectively, by the end of the study. All patients completed virtual training successfully. Conclusions: Our findings confirm that the use of MiniMed™ 670 System allows patients to achieve glycemic control within recommended targets in a non-selected population in Argentina. Virtual education appears to be suitable for patient training on HCL therapy during current COVID-19 pandemic situation. Disclosure: A. E. Proietti: None. M. P. Santucci: None. M. Castro: Employee; Spouse/Partner; Medtronic. A. Daghero: Employee; Spouse/Partner; Medtronic. L. A. Grosembacher: None. M. A. Angós: None. A. Dain: None. M. I. Echenique: None. M. L. Kabakian: Speaker's Bureau; Self; Abbott, Medtronic. M. P. Paz: Speaker's Bureau; Self; Medtronic. M. Raggio: Speaker's Bureau; Self; Abbott, Medtronic, Roche Diabetes Care. G. B. Rubin: None. A. Saleme: Advisory Panel; Spouse/Partner; Abbott Diabetes, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
